Business Wire

OH-FORGE-BIOLOGICS

Share
Forge Biologics’ Novel AAV Gene Therapy FBX-101 for Patients with Krabbe Disease is Granted UK’s Innovation Passport Designation

Forge Biologics, a member of Ajinomoto Bio-Pharma Services and a leading manufacturer of genetic medicines, today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA), the healthcare regulatory body of the United Kingdom (UK), granted Innovation Passport designation to the Company’s novel AAV gene therapy program, FBX-101, to enter the Innovative Licensing and Access Pathway (ILAP). FBX-101 was created for the treatment of patients with Krabbe disease, a rare neurodegenerative disease that is usually fatal in untreated patients by age two. The ILAP is intended to accelerate regulatory and market access interactions in the UK.

Maria Escolar, M.D., Forge’s Chief Medical Officer, will discuss the significance of achieving this regulatory designation and present a poster on updated data from REKLAIM, an early phase clinical trial for FBX-101, during the Advanced Therapies 2024 conference being held in London, March 19-20, 2024.

“Considering the rapid progression of Krabbe disease in young patients and the positive results we’ve observed in the REKLAIM trial, we are pleased to receive the Innovation Passport designation which will enable Forge to further accelerate the clinical development of FBX-101,” stated Dr. Escolar. “ILAP was created to provide access to tools to decrease the time to market and facilitate patient access to medicines in the UK for life-threatening or seriously debilitating conditions.”

The REKLAIM clinical trial is evaluating the safety and efficacy of FBX-101 in patients with infantile and late infantile Krabbe disease. Children assessed in REKLAIM have received intravenous FBX-101 in addition to the current standard of care, hematopoietic stem cell transplantation (HSCT). Clinical data demonstrate that FBX 101 has been well tolerated and has an excellent safety profile after the treatment of five patients. Results show improvements in motor function in all patients, the most meaningful clinical outcome for this disease.

FBX-101 has been granted Orphan Drug Designation and Priority Medicines (PRIME) designation by the European Medicines Agency (EMA), allowing Forge to advance and expedite the development of FBX-101 as the leading worldwide gene therapy for patients with Krabbe disease. In the US, the FDA has granted FBX-101 Fast Track Designation, Orphan Drug Designation, and Rare Pediatric Disease Designation.

ILAP is intended to accelerate regulatory and market access interactions in the UK for patient populations with significant need, leading to accelerated patient access to novel therapies. It also provides access to a range of UK development services and tools, including frequent MHRA interactions, accelerated Marketing Authorization Application (MAA) assessment, a Target Development Profile, expanded licensing routes, and more, creating a roadmap for advancement of therapies through regulatory approval.

Regulatory review by the MHRA through ILAP provides opportunities for further global acceptance of Forge’s manufacturing process and facility though additional reviews and inspections, including Compliance Readiness Inspections that provide custom and pragmatic supervisory and licensing inspections specific to the GMP guidelines. Through this designation Forge has expanded global regulatory experience to include interactions with the MHRA in the UK. This access to global health authority resources will enable an added level of assurance to clients utilizing Forge’s CDMO services with integrated regulatory support.

About Krabbe Disease

Krabbe disease is a rare neurodegenerative disease affecting about 1-2.5 in 100,000 people in the US. Krabbe disease is caused by autosomal recessive mutations in the galactocerebrosidase (GALC) gene, an enzyme responsible for the breakdown of certain types of sphingolipids, such as psychosine. Without functional GALC, psychosine accumulates to toxic levels in cells, specifically in cells insulating the nerves in the brain and peripheral nervous system, causing rapid demyelination. Krabbe disease initially manifests in young patients as irritability, developmental delay, and progressive muscle weakness. Symptoms rapidly advance to difficulty swallowing, breathing, and regression of neurodevelopment followed by seizures, vision and hearing loss. Infantile Krabbe disease (0-12 months of age at onset) usually leads to death in untreated patients by two years of age. Late Infantile patients (12-36 months of age at onset) usually die by the age of six. The current standard of care, hematopoietic stem cell transplantation (HSCT), has been shown to stabilize cognitive decline and significantly improve long-term neurological outcomes. However, HSCT does not correct the peripheral neuropathy that is progressive as the patient grows, leading to loss of gross motor skills and eventually death.

About FBX-101

FBX-101 was developed to treat children with Krabbe disease. FBX-101 is an adeno-associated viral serotype rh10 (AAVrh10) gene therapy that is delivered intravenously after HSCT infusion. The vector delivers a functional copy of the GALC gene to cells in both the central and peripheral nervous system and has shown to functionally correct the central and peripheral neuropathy, improve myelination and gross motor function, and significantly prolong lifespan in animal models. This approach also has the potential to overcome some of the immunological safety challenges observed in traditional AAV gene therapies and extend the duration of gene transfer.

About the REKLAIM Trial

REKLAIM is a nonblinded, non-randomized, early phase dose escalation clinical trial currently enrolling children with asymptomatic infantile and symptomatic late infantile Krabbe disease to investigate the safety and efficacy of a single intravenous infusion of FBX-101 administered more than 21 days after HSCT, the current standard of care. Data from extensive natural history subjects will be used to compare as the control group. More information on the REKLAIM trial can be found online at https://www.clinicaltrials.gov/ct2/show/NCT05739643.

About Forge Biologics

Forge Biologics, a member of Ajinomoto Bio-Pharma Services, is a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company, enabling access to life-changing gene therapies by bringing them from concept to reality. Forge’s 200,000 square foot facility, the Hearth, is headquartered in Columbus, Ohio, and houses 20 custom-designed cGMP suites with 200,000L of manufacturing capacity. Forge’s end-to-end, scalable plasmid and AAV manufacturing services include research-grade manufacturing, process and analytical development, cGMP manufacturing, fill and finish, and integrated regulatory support to help accelerate the timelines of transformative medicines for patients with genetic diseases. To learn more, visit www.forgebiologics.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240319976189/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Nanoco Refocuses on Strategic Growth11.2.2025 13:00:00 CET | Press release

Nanoco Group PLC (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other advanced nanomaterials, has completed several organisational changes designed to accelerate its commercial development. In October 2024, Dmitry Shashkov joined as Chief Executive Officer. He has a proven 20 year plus track record in leading materials science-based businesses, driving shareholder value through transformational business development. Dmitry was CEO of the CPS Group of companies (later part of Exyte), which focused on high-tech equipment for semiconductors and life science industries. Under his leadership, CPS revenues tripled, and profitability increased fourfold before its sale to a strategic investor. Prior to CPS, Dmitry was President and CEO of H.C. Starck Inc. (a world-leading supplier of refractory metals) and Business Director at Honeywell (a leading supplier of electronic materials). He began his career with McKinsey & Company, advising clients in

Accelera to Power 100 MW Electrolyzer System for bp’s Lingen Green Hydrogen Project11.2.2025 13:00:00 CET | Press release

Accelera™ by Cummins, the zero-emissions business segment of Cummins Inc. [NYSE: CMI], will supply a 100-megawatt (MW) proton exchange membrane (PEM) electrolyzer system for bp's Lingen green hydrogen project in Germany. This project, bp's largest hydrogen production plant to date, will utilize Accelera's advanced HyLYZER® PEM electrolyzer technology. The hydrogen-generation system set to power bp’s Lingen project will consist of 20 PEM HyLYZER®-1000 electrolyzer units — the largest electrolyzer system assembled by Accelera to date — and is being manufactured in Accelera’s new electrolyzer plant in Guadalajara, Spain. Once fully commissioned in 2027, the 100 MW electrolyzer system will produce up to 11,000 tons of green hydrogen per year. "This project marks a significant milestone for Accelera and the energy transition in Germany and Europe," said Andreas Lippert, Vice President and General Manager of Electrolyzers for Accelera. “Partnering on this 100 MW system with an industry leade

comforte AG Warns of Impending March 2025 PCI DSS 4.0 Compliance Deadline11.2.2025 10:41:00 CET | Press release

comforte AG, a global leader in data security, today urged global businesses to finalize their PCI DSS 4.0 plans, ahead of the compliance deadline which falls on 31 March 2025. PCI DSS 4.0 is a major new iteration of the Payment Card Industry Data Security Standard, which applies to any organization which stores, processes or transmits cardholder data. As such, it has an outsized impact on sectors such as financial services and retail. The latest version features over 50 new technical requirements including new rules around data protection mechanisms. A key focus for PCI DSS 4.0 is to encourage cybersecurity as a long-term, continuous process, which is why additional flexibility has been baked into the standard—allowing organizations to choose the security controls most suited to their business. comforte’s tokenization technology is a proven, format-preserving way to safeguard cardholder data in line with PCI DSS 4.0, while preserving data utility. Because sensitive data elements like

Xsolla and AppsFlyer Unveil Custom Integration to Boost Mobile Game Web Shop Performance11.2.2025 10:00:00 CET | Press release

Industry First Collaboration Introduces Cross-Platform Analytics as an Integrated Solution to Solve Mobile and Web Measurement Challenges for Game Developers Xsolla, a leading global video game commerce company, has partnered with AppsFlyer, the global leader in mobile measurement, attribution, and data analytics, in a first-in-the-gaming industry web shop collaboration. This enhancement of the Xsolla and AppsFlyer partnership provides game developers with improved insights and simplified activation for its Web Shop solution, which is available worldwide. It also introduces solutions to address cross-platform measurement and attribution challenges. The partnership includes two integration options: server-to-server (S2S) and web integrations for mobile games. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250211661118/en/ (Graphic: Xsolla) Xsolla and AppsFlyer have collaborated closely for over a year to develop two custom in

Dragon Elements Breaks Free From Screens With LATIDO® Capsules11.2.2025 10:00:00 CET | Press release

SCALE Nanotech spins out Dragon Elements to bring graphene-based audiovisual technology to the XR and wearable electronics market SCALE Nanotech, an advanced R&D company based in Estonia, has announced the launch of its spinout Dragon Elements in Spain, marking a disruptive entry into the XR and wearable electronics sector. Dragon Elements is set to commercialize LATIDO® capsules, a revolutionary graphene-based technology designed to redefine human interaction with hardware by eliminating the need for traditional audio and video components. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250211733484/en/ The Birth of LATIDO®: A New Paradigm in Audiovisual Technology Derived from the Spanish word latido (heartbeat), LATIDO® encapsulates a radical shift in audiovisual hardware. Unlike conventional technology that requires separate components for sound and vision, LATIDO® harnesses millions of one-atom-thick graphene membranes t

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye